Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Phase I trial of the combination of bortezomib and clofarabine in adults with refractory tumors.
Journal: Cancer chemotherapy and pharmacology
Published: November 21, 2025
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Journal: Cancer discovery
Published: February 02, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Journal: Lancet (London, England)
Published: August 09, 2023
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: June 06, 2023
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 06, 2021
Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 17, 2021
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas.
Journal: Oncotarget
Published: July 13, 2020
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 29, 2017
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
Journal: Drugs
Published: January 13, 2017
Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.
Journal: Bone marrow transplantation
Published: January 05, 2016
New treatment option for ovarian cancer: PARP inhibitors.
Journal: Gynecologic oncology research and practice
Published: October 18, 2015
Last Updated: 09/26/2026